Quantum-Si’s Next-Generation Single-Molecule Protein Sequencing Technology Published in Science, Signaling New Era of Life Science and Biomedical Research
Semiconductor Chip and Time Domain Sequencing™ Technology Will Advance Drug Discovery and Diagnostics, Enabling People to Live Healthier and Longer Lives
- Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body — just as the advent of next-generation DNA sequencing has revolutionized our knowledge of the human genome over the past two decades.
- Through its real-time amino acid sequencing approach,
Quantum-Siis on the forefront of commercializing the first platform that will offer an accessible and accurate understanding of proteins with single-molecule resolution — without the roadblocks of complex chemistry and large, expensive equipment — enabling groundbreaking research that will ultimately help people live healthier and longer lives.
- This is the first paper from any company demonstrating protein sequencing technology that has been published in a major peer-reviewed journal, serving to showcase the unparalleled innovation behind Quantum-Si’s technology and how it will shape the future of proteomics.
Founded by world-renowned scientist, entrepreneur, and National Medal of Technology and Innovation recipient Dr.
“I am proud and excited to share the first next-generation single-molecule protein sequencing technology with the world,” said
As described in Science’s publication of “Real-time dynamic single-molecule protein sequencing on an integrated semiconductor device,” Quantum-Si’s semiconductor chip contains millions of wells, allowing for the cataloging of many proteins in parallel and the understanding of how these proteins are modified at the single-molecule level. The company’s next-generation sequencing system detects and cleaves amino acids using proteins and enzymes derived from naturally occurring pathways that carry out a similar process in cells. This approach eliminates roadblocks of complex chemistry and large, expensive equipment facing other technologies, while providing the sensitivity, scalability, and accessibility needed to accelerate biomedical research.
"The concept of a small benchtop instrument carrying out massively-parallel sequencing of individual protein molecules was previously unimaginable,” said
Additional information on Quantum-Si’s single-molecule protein sequencing process, as outlined in the Science study, include:
- A dynamic approach in which single peptides are probed in real-time by a mixture of dye-labeled N-terminal amino acid recognizers and simultaneously cleaved by aminopeptidases;
- Annotation of amino acids and identification of the peptide sequence by measuring fluorescence intensity, lifetime, and binding kinetics on an integrated semiconductor chip;
- Recognizers identify multiple amino acids in an information-rich manner that enables discrimination of single amino acid substitutions and post-translational modifications (PTMs), allowing for a more detailed picture of individual proteins and their variations for future disease identification and prevention.
The peer-reviewed article titled “Real-time dynamic single-molecule protein sequencing on an integrated semiconductor” appears in the
To learn more about
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on